Brief: Hanmi Pharm Co Enters License Agreement With Eli Lilly For Sonefpeglutide
BRIEF-Hanmi Pharm Co Enters License Agreement With Eli Lilly For Sonefpeglutide May 31 (Reuters) - Hanmi Pharm Co Ltd 128940.KS:
HANMI PHARM CO - ENTERS LICENSE AGREEMENT WITH LILLY FOR SONEFPEGLUTIDE
HANMI PHARM CO - LILLY OBTAINS EXCLUSIVE GLOBAL RIGHTS TO SONEFPEGLUTIDE EXCLUDING KOREA
HANMI PHARM CO - TO RECEIVE $75 MLN UPFRONT AND UP TO $1.19 BLN IN MILESTONES
Source text: ID:nPre78LC8a
Further company coverage: 128940.KS
((Reuters.briefs@thomsonreuters.com;))
Recent news on Eli Lilly and Co
See all newsAntares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
Absci rises on positive hair-loss drug data
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
HK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)